Rosemary, sage could boost brain health: Study
(NewsNation) — A recent study has found that rosemary and sage may have a positive impact on brain health and reduce the risk of Alzheimer's disease.
The study released in the Antioxidants journal shows a compound shared by the two herbs called carnosic acid has antioxidant and anti-inflammatory properties that shield brain cells from damage similar to what can lead to Alzheimer's. Researchers were able to create a more stable form of carnosic acid called diAcCA.
Screen time a symptom, cause of emotional distress in kids: Study
In preclinical studies, the researchers found that the compound improved memory, boosted brain synapses and reduced harmful Alzheimer's-related proteins like amyloid-beta and tau.
The diAcCA compound only activates in inflamed brain regions, which could minimize side effects. To date, studies in mice have shown significant cognitive improvements and no signs of toxicity. Researchers are looking to start human trials soon.
Researchers also believe diAcCA could help treat other inflammatory conditions, such as Type 2 diabetes, cardiovascular disease and Parkinson's disease.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Merry Life Launches Global Phase II Trial of TML-6, The First Drug Targeted at Autolysosome pathway for Therapy of Alzheimer's Disease
TAINAN, June 12, 2025 /PRNewswire/ -- Merry Life Biomedical Company announces the launch of its global Phase II clinical trial for TML-6, a novel oral small molecule drug targeting early-stage Alzheimer's disease (AD). TML-6 combines multiple mechanisms, including anti-oxidative effects (Nrf2 activation), melioration of autophagy function (autolysosomal activation), anti-amyloid accumulation (β-amyloid clearance), and anti-inflammatory effects (through NF-κB inhibition) through autolysosome pathway in neurons and microglia to remove intraneuronal and extracellular amyloid accumulation, representing the first in human multi-target strategy for AD treatment. The Phase I trial showed excellent safety, tolerability, and pharmacokinetics at 100–200 mg in both healthy and elderly adults. TML-6 will now advance to a Phase II 19 site trial across the United States, Sweden, and Taiwan after FDA approval. This 12-month study will enroll 210 patients with mild cognitive impairment (MCI) or mild dementia. Primary endpoints will include neuropsychological assessments (CDR-SB, iADRS) and blood biomarkers (p-Tau 217, Aβ42/40, NfL, GFAP), supported by brain MRI, amyloid PET scans, and ApoE genotyping. Type C FDA consultation for phase 2 trial design has completed on 13 May 2025, with trial initiation expected in April 2026, conducted by Syneos Health CRO. With its strong preclinical and clinical profile, TML-6 holds promise as both a monotherapy and in combination with anti-amyloid biologics, providing new hope for patients with Alzheimer's disease. About Merry Life Biomedical Company Merry Life Biomedical is a Taiwan-based biotechnology company focused on developing innovative therapies for neurodegenerative and age-related diseases. Leveraging advanced molecular design, pharmacological innovation, formulation optimization and global clinical development, the company is committed to addressing urgent unmet medical needs. Media ContactDr. Ih-Jen SuMerry Life Biomedical Company, +886-910-902-296Email: suihjen0704@ View original content to download multimedia: SOURCE Merry Life Biomedical Company, Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Hampton Roads infant with rare genetic disorder in critical need of liver donor
PORTSMOUTH, Va. (WAVY) – Infant Rhett Powell will celebrate his first birthday Friday, but his parents are hoping to give him something far greater than a toy; they want him to have the gift of life. Rhett was diagnosed at just two months' old with a rare genetic disorder, Alagille Syndrome. Only about 1 in every 30,000 babies are born with the condition, according to the National Institutes of Health. His mother, Jenna, never imagined Rhett would be part of that statistic. At 10 months, doctors revealed his condition was compounded with liver disease and his parents also learned he would need a liver transplant. 'There's also a lot of risk with the transplant,' she says. 'And we know that the risk of a transplant outweighs keeping his liver the way it is. So, there's a mix of emotions: sadness, happiness, excitement, nervousness, all of the above. Alagille Syndrome is known to cause narrowed and malformed bile ducts in the liver, which is one of Rhett's toughest hurdles. His condition causes jaundice, issues with his heart and eyes, and itching so severe that he scratches until he bleeds. His blood is also highly acidic. Jenna says Rhett only weighs 16 lbs. and is on a feeding tube. His father was left with no choice but to quit his job as he can't crawl or move on his own. For the past two months, Jenna has been searching high and low for a liver donor who could be her baby boy's perfect match. 'His perfect match would be someone that has B or O blood type,' she says. 'Negative or positive, it doesn't matter. There would need to be aged around, 18 to 60. Nonsmoker, someone with no major organ diseases or preexisting conditions like diabetes or high blood pressure. No major abdominal surgeries; no illicit drug use. And someone that is willing to do that.' If you think you may be a match or know of someone who could be a match, you can contact Jenna Powell at (757) 556-5182. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
4 hours ago
- Yahoo
Water Quality Advisory Issued for Okaloosa County locations
OKALOOSA COUNTY, Fla. (WMBB) – The Florida Department of Health in Okaloosa County has issued a water quality advisory for multiple locations in Fort Walton and Niceville. The following locations did not meet the recreational water quality criteria for Enterococcus bacteria according to a test on June 9th: Liza Jackson Park, 338 Miracle Strip Parkway SW, Fort Walton Beach Emerald Promenade, 933 Whelk Court, Fort Walton Beach Rocky Bayou State Park, 4281 Highway 20, Niceville Enterococci are enteric bacteria that normally inhabit the intestinal tract of humans and animals; their presence could be an indication of fecal pollution. More information on the test results can be found here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
